GeneDx Partners with Zevra Therapeutics on NPC Genetic Testing Program
Event summary
- GeneDx and Zevra Therapeutics launched a genetic testing program for Niemann-Pick Disease Type C (NPC) on March 10, 2026.
- The program offers GeneDx’s ExomeDx™ test at no charge to eligible U.S. patients with suspected NPC.
- Zevra Therapeutics will financially support the program as part of its commitment to advancing NPC diagnosis and care.
- De-identified data from the program will be added to GeneDx Infinity™, the largest rare disease dataset.
The big picture
This collaboration underscores the growing importance of early and accurate genetic diagnosis in rare disease treatment, particularly as new therapeutic options emerge. The program aligns with broader industry trends toward precision medicine and data-driven healthcare solutions. GeneDx’s ExomeDx™ test has been granted FDA Breakthrough Device designation, highlighting its significance in the diagnostic landscape.
What we're watching
- Diagnostic Speed
- How the program will affect the pace of NPC diagnosis and treatment initiation.
- Data Utilization
- Whether GeneDx Infinity™ dataset will accelerate rare disease research beyond NPC.
- Market Expansion
- The extent to which this partnership model can be replicated for other rare diseases.
Related topics